Management of anticoagulation in elderly patients represents a particularly challenging issue. Indeed, this patient population is at high thromboembolic risk, but also at high hemorrhagic risk. Assessment of the benefit-risk balance of anticoagulation is the key point when decisions are made about introducing and/or continuing such treatments in the individual elderly patient. In order to maximise the safety of anticoagulation in the elderly, some specific considerations need to be taken into account, including renal insufficiency, modified pharmacodynamics of anticoagulants, especially vitamin K antagonists, and the presence of multiple comorbidities and concomitant medications. New anticoagulants could greatly simplify and possibly increase the safety of anticoagulation in the elderly in the near future. © 2010 by the authors; licensee MDPI, Basel, Switzerland.
CITATION STYLE
Robert-Ebadi, H., & Righini, M. (2010). Anticoagulation in the elderly. Pharmaceuticals. MDPI AG. https://doi.org/10.3390/ph3123543
Mendeley helps you to discover research relevant for your work.